On May 28, GLONGHUI (002653.SZ) announced that its subsidiary, Sichuan Hisco Pharmaceutical Co., Ltd. received the “Notice of Acceptance” issued by the State Drug Administration on May 28, 2024, which is HSK44459 tablets.
HSK44459 tablets are a brand new drug independently developed by the company to treat interstitial lung disease with independent intellectual property rights. According to the requirements for chemical drug registration classification in the notice issued by the State Drug Administration on the “Registration Classification of Chemical Drugs and Application Data Requirements” (No. 44 of 2020), this product is a chemical drug category 1.
Preclinical research results show that HSK44459 has clear targets, accurate efficacy, and good safety. It is a small molecule drug with great potential for development. It has a high benefit/risk ratio for clinical application, and has broad clinical application prospects. It is expected to become an effective treatment for interstitial lung disease and solve the current problem of lack of clinical medication.